Replies to post #209345 on Biotech Values

[DewDiligence]

…if EXAS can eliminate an invasive biopsy on lung nodules…

That would indeed be a big breakthrough, but it’s a much tougher task than detecting biomarkers for CRC in a stool sample (what Cologuard does).

…all their diagnostics will use the same platform as CG quarts, so no huge capex.

I’m not sure what you mean by quarts—please clarify.